| Literature DB >> 19148285 |
Wilfredo Hernándeza1, Juan Paz, Abraham Vaisberg, Evgenia Spodine, Rainer Richter, Lothar Beyer.
Abstract
The palladium (II) bis-chelate Pd (L(1-3))(2) and platinum (II) tetranuclear Pt(4)(L(4))(4) complexes of benzaldehyde thiosemicarbazone derivatives have been synthesized, and characterized by elemental analysis and IR, FAB(+)-mass and NMR ((1)H, (13)C) spectroscopy. The complex Pd(L(2))(2) [HL(2) = m-CN-benzaldehyde thiosemicarbazone] shows a square-planar geometry with two deprotonated ligands (L) coordinated to Pd(II) through the nitrogen and sulphur atoms in a transarrangement, while the complex Pt(4)(L(4))(4) [HL(4) = 4-phenyl-1-benzaldehyde thiosemicarbazone] has a tetranuclear geometry with four tridentate ligands coordinated to four Pt(II) ions through the carbon (aromatic ring), nitrogen, and sulphur atoms where the ligands are deprotonated at the NH group. The in vitro antitumor activity of the ligands and their complexes was determined against different human tumor cell lines, which revealed that the palladium (II) and platinum (II) complexes are more cytotoxic than their ligands with IC(50) values at the range of 0.07-3.67 microM. The tetranuclear complex Pt(4)(L(4))(4), with the phenyl group in the terminal amine of the ligand, showed higher antiproliferative activity (CI(50) = 0.07-0.12 microM) than the other tested palladium (II) complexes.Entities:
Year: 2009 PMID: 19148285 PMCID: PMC2615113 DOI: 10.1155/2008/690952
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Synthesis of the benzaldehyde thiosemicarbazone and 4-phenyl-1-benzaldehyde thiosemicarbazone ligands.
Crystal data and refinement summary.
| HL4 | Pd(L2)2·H2O | Pt4(L4)4·2C2H5OH | |
|---|---|---|---|
| Empirical formula | C14H13N3S | C18H16N8OPdS2 | C60H56N12O2Pt4S4 |
| Formula weight (g/mol) | 255.33 | 530.91 | 1885.77 |
| Crystal habit, color | Yellow plates | Orange prisms | Red prisms |
| Crystal system | Triclinic | Monoclinic | Monoclinic |
| Space group | P-1 | C2/c | P21 |
| a (Å) | 5.988(1) | 20.016(4) | 12.708(1) |
| b (Å) | 10.285(2) | 6.421(1) | 13.639(1) |
| c (Å) | 11.410(2) | 18.511(4) | 17.031(1) |
|
| 68.040(2) | ||
|
| 82.514(3) | 120.78(3) | 94.054(1) |
|
| 86.886(2) | ||
| Volume (Å3) | 646.1(2) | 2044.0(7) | 2944.5(3) |
| Z; F(000) | 2; 268 | 4; 1064 | 2; 1784 |
| Densitycalc (g/cm3) | 1.313 | 1.725 | 2.127 |
| Crystal size (mm) | 0.44 × 0.20 × 0.04 | 0.43 × 0.39 × 0.07 | 0.16 × 0.16 × 0.05 |
|
| 0.235 | 1.141 | 9.669 |
| 2 | 3.8–50.0 | 6.8–56.2 | 3.8–59.0 |
| Temperature (K) | 220 | 213 | 213 |
| Measured reflections | 3388 | 9478 | 19123 |
|
| 0.0290 | 0.0635 | 0.0224 |
| Unique reflections | 2252 | 2462 | 13693 |
| Observed reflections
( | 1939 | 2012 | 12253 |
| Refined parameters | 215 | 170 | 713 |
|
| 0.1693 | 0.0929 | 0.0774 |
|
| 0.0618 | 0.0331 | 0.0338 |
| Largest difference peak and hole (e/ Å3) | 0.38/−0.31 | 1.26/−0.88 | 1.71/−1.14 |
Figure 1Molecular structure of HL4.
Figure 2Molecular structure of Pd(L2)2.
Figure 3Molecular structure of Pt4(L4)4.
Selected bond lengths (Å) for the HL4 ligand and the Pd(L2)2 and Pt4(L4)4 complexes.
| HL4 | Pd(L2)2 | Pt4(L4)4 | |
|---|---|---|---|
| S1–C1 | 1.686(3) | 1.746(2) | 1.812(9) |
| N1–N2 | 1.378(4) | 1.378(2) | 1.389(10) |
| N1–C8 | 1.284(4) | 1.293(11) | |
| N2–C1 | 1.354(4) | 1.296(11) | |
| N3–C1 | 1.342(4) | 1.348(3) | 1.354(11) |
| N3–C2 | 1.422(4) | 1.427(12) | |
| C2–C3 | 1.472(3) | ||
| C8–C9 | 1.457(4) | 1.441(13) | |
| N1–C1 | 1.316(3) | ||
| N2–C2 | 1.306(3) | ||
| Pd1–S1 | 2.297(1) | ||
| Pd1–N2 | 2.049(2) | ||
| Pt–S (intraligand) | 2.351(2) | ||
| Pt–S′(bridging) | 2.298(2) | ||
| Pt–N1 | 1.991(7) | ||
| Pt–C10 | 2.015(8) |
Selected bond angles (°) for the HL4 ligand and the Pd(L2)2 and Pt4(L4)4 complexes.
| HL4 | Pd(L2)2 | Pt4(L4)4 | |
|---|---|---|---|
| N2–N1–C8 | 115.0(3) | 118.5(7) | |
| N1–N2–C1 | 119.8(3) | 113.4(7) | |
| C1–N3–C2 | 127.7(3) | 127.6(8) | |
| S1–C1–N2 | 118.7(2) | 124.8(7) | |
| S1–C1–N3 | 126.1(2) | 117.4(2) | 114.4(7) |
| N2–C1–N3 | 115.2(3) | 120.7(8) | |
| N1–C8–C9 | 121.8(3) | 115.0(8) | |
| N2–N1–C1 | 113.5(2) | ||
| N1–N2–C2 | 116.5(2) | ||
| S1–C1–N1 | 125.3(2) | ||
| N1–C1–N3 | 117.3(2) | ||
| N2–C2–C3 | 131.6(2) | ||
| S1–Pd1–N2 | 82.8(1) | ||
| S–Pt–N1 | 83.1(2) | ||
| N1–Pt–C10 | 80.9(3) | ||
| C10–Pt-S′ | 94.8(3) | ||
| S–Pt–S′ | 101.5(1) | ||
| Pt–S1–S1 | 93.6(3) | ||
| Pt–N1–N2 | 124.2(5) | ||
| Pt–N1–C8 | 117.2(6) |
IC50(μM) values of the palladium complexes, Pd(1–3)2, and the platinum tetranuclear complex, Pt4(L4)4, against the different human tumor cell lines.
| Human tumor cell lines | Pd(L1)2 | Pd(L2)2 | Pd(L3)2 | Pt4(L4)4 |
|---|---|---|---|---|
| Lung large cell carcinoma (H460) | 8.73 | 3.53 | 5.82 | 0.09 |
| Cervix epidermoid carcinoma (ME180) | 10.47 | 3.67 | 8.06 | 0.12 |
| Prostate carcinoma (DU145) | 11.59 | 1.99 | 9.30 | 0.10 |
| Breast adenocarcinoma (MCF-7) | 8.18 | 2.09 | 6.14 | 0.08 |
| Amelanotic melanoma (M-14) | 12.46 | 1.87 | 8.74 | 0.11 |
| Colon adenocarcinoma (HT-29) | 7.45 | 1.35 | 5.96 | 0.07 |
| Prostate carcinoma (PC-3) | 10.20 | 1.56 | 7.36 | 0.08 |
| Chronic myelogenous leukemia (K562) | 6.15 | 0.45 | 3.04 | 0.08 |
(a)Cl50 corresponds to the concentration required to inhibit a 50% of the cell growth when the cells are exposed to the compounds during 48 hours. Each value is the average of two independent experiments.